45 related articles for article (PubMed ID: 7860149)
1. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
[TBL] [Abstract][Full Text] [Related]
2. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
[TBL] [Abstract][Full Text] [Related]
3. Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha.
Hoffmann M; Schmidt M; Wels W
Cancer Immunol Immunother; 1998 Nov; 47(3):167-75. PubMed ID: 9829842
[TBL] [Abstract][Full Text] [Related]
4. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors.
Zielinski R; Lyakhov I; Hassan M; Kuban M; Shafer-Weaver K; Gandjbakhche A; Capala J
Clin Cancer Res; 2011 Aug; 17(15):5071-81. PubMed ID: 21791637
[TBL] [Abstract][Full Text] [Related]
5. Co-Expression of a Chimeric Protease Inhibitor Secreted by a Tumor-Targeted
Quintero D; Carrafa J; Vincent L; Lee HJ; Wohlschlegel J; Bermudes D
J Microbiol Biotechnol; 2018 Dec; 28(12):2079-2094. PubMed ID: 30661346
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas.
von Minckwitz G; Harder S; Hövelmann S; Jäger E; Al-Batran SE; Loibl S; Atmaca A; Cimpoiasu C; Neumann A; Abera A; Knuth A; Kaufmann M; Jäger D; Maurer AB; Wels WS
Breast Cancer Res; 2005; 7(5):R617-26. PubMed ID: 16168106
[TBL] [Abstract][Full Text] [Related]
7. ErbB expression: the mouse inner ear and maturation of the mitogenic response to heregulin.
Hume CR; Kirkegaard M; Oesterle EC
J Assoc Res Otolaryngol; 2003 Sep; 4(3):422-43. PubMed ID: 14690060
[TBL] [Abstract][Full Text] [Related]
8. Role of heregulin in human cancer.
Breuleux M
Cell Mol Life Sci; 2007 Sep; 64(18):2358-77. PubMed ID: 17530167
[TBL] [Abstract][Full Text] [Related]
9. Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.
Schappa JT; Frantz AM; Gorden BH; Dickerson EB; Vallera DA; Modiano JF
Int J Cancer; 2013 Oct; 133(8):1936-44. PubMed ID: 23553371
[TBL] [Abstract][Full Text] [Related]
10. Inhibition by transmembrane peptides of chimeric insulin receptors.
Bennasroune A; Gardin A; Auzan C; Clauser E; Dirrig-Grosch S; Meira M; Appert-Collin A; Aunis D; Crémel G; Hubert P
Cell Mol Life Sci; 2005 Sep; 62(18):2124-31. PubMed ID: 16132228
[TBL] [Abstract][Full Text] [Related]
11. Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras.
Nachreiner I; Hussain AF; Wullner U; Machuy N; Meyer TF; Fischer R; Gattenlöhner S; Meinhold-Heerlein I; Barth S; Tur MK
Exp Ther Med; 2019 Oct; 18(4):2401-2412. PubMed ID: 31555351
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.
Mota JM; Collier KA; Barros Costa RL; Taxter T; Kalyan A; Leite CA; Chae YK; Giles FJ; Carneiro BA
Oncotarget; 2017 Oct; 8(51):89284-89306. PubMed ID: 29179520
[TBL] [Abstract][Full Text] [Related]
13. Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles.
Hwang JY; Park J; Kang BJ; Lubow DJ; Chu D; Farkas DL; Shung KK; Medina-Kauwe LK
PLoS One; 2012; 7(4):e34463. PubMed ID: 22509306
[TBL] [Abstract][Full Text] [Related]
14. EGFR/HER-targeted therapeutics in ovarian cancer.
Wilken JA; Badri T; Cross S; Raji R; Santin AD; Schwartz P; Branscum AJ; Baron AT; Sakhitab AI; Maihle NJ
Future Med Chem; 2012 Mar; 4(4):447-69. PubMed ID: 22416774
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy targeting by DNA capture in viral protein particles.
Agadjanian H; Chu D; Hwang JY; Wachsmann-Hogiu S; Rentsendorj A; Song L; Valluripalli V; Lubow J; Ma J; Sharifi B; Farkas DL; Medina-Kauwe LK
Nanomedicine (Lond); 2012 Mar; 7(3):335-52. PubMed ID: 22385197
[TBL] [Abstract][Full Text] [Related]
16. Tumor detection and elimination by a targeted gallium corrole.
Agadjanian H; Ma J; Rentsendorj A; Valluripalli V; Hwang JY; Mahammed A; Farkas DL; Gray HB; Gross Z; Medina-Kauwe LK
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6105-10. PubMed ID: 19342490
[TBL] [Abstract][Full Text] [Related]
17. Specific delivery of corroles to cells via noncovalent conjugates with viral proteins.
Agadjanian H; Weaver JJ; Mahammed A; Rentsendorj A; Bass S; Kim J; Dmochowski IJ; Margalit R; Gray HB; Gross Z; Medina-Kauwe LK
Pharm Res; 2006 Feb; 23(2):367-77. PubMed ID: 16411149
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting and inducible destruction of human cancer cells by retroviruses with envelope proteins bearing short peptide ligands.
Gollan TJ; Green MR
J Virol; 2002 Apr; 76(7):3564-9. PubMed ID: 11884581
[TBL] [Abstract][Full Text] [Related]
19. Agrin can mediate acetylcholine receptor gene expression in muscle by aggregation of muscle-derived neuregulins.
Meier T; Masciulli F; Moore C; Schoumacher F; Eppenberger U; Denzer AJ; Jones G; Brenner HR
J Cell Biol; 1998 May; 141(3):715-26. PubMed ID: 9566971
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
Schmidt M; Wels W
Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
